EA202092006A1 - CD83-BINDING CHIMERIC ANTIGENIC RECEPTORS - Google Patents

CD83-BINDING CHIMERIC ANTIGENIC RECEPTORS

Info

Publication number
EA202092006A1
EA202092006A1 EA202092006A EA202092006A EA202092006A1 EA 202092006 A1 EA202092006 A1 EA 202092006A1 EA 202092006 A EA202092006 A EA 202092006A EA 202092006 A EA202092006 A EA 202092006A EA 202092006 A1 EA202092006 A1 EA 202092006A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disclosed
cells
donor cells
express
cars
Prior art date
Application number
EA202092006A
Other languages
Russian (ru)
Inventor
Марко Дейвила
Брайан Беттс
Original Assignee
Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют Инк. filed Critical Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют Инк.
Priority claimed from PCT/US2019/019065 external-priority patent/WO2019165156A1/en
Publication of EA202092006A1 publication Critical patent/EA202092006A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Раскрыты композиции и способы предупреждения болезни "трансплантат против хозяина" (GVHD) у субъектов, получающих донорские клетки. В частности, раскрыты полипептиды химерного антигенного рецептора (CAR), которые можно использовать совместно с адоптивным переносом клеток для подавления аллореактивных донорских клеток. Также раскрыты иммунные эффекторные клетки, такие как Т-клетки или естественные клетки-киллеры (NK), которые сконструированы с обеспечением экспрессии таких CAR. Соответственно, также раскрыты способы подавления аллореактивных донорских клеток у субъекта, получающего донорские клетки при трансплантации, которые предусматривают адоптивный перенос раскрытых иммунных эффекторных клеток, сконструированных с обеспечением экспрессии раскрытых CAR.Compositions and methods of preventing graft versus host disease (GVHD) in subjects receiving donor cells are disclosed. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used in conjunction with adoptive cell transfer to suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or natural killer (NK) cells, that are engineered to express such CARs. Accordingly, methods of inhibition of alloreactive donor cells in a subject receiving donor cells by transplant are also disclosed, which involve adoptive transfer of disclosed immune effector cells engineered to express disclosed CARs.

EA202092006A 2018-05-30 2019-02-22 CD83-BINDING CHIMERIC ANTIGENIC RECEPTORS EA202092006A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862677783P 2018-05-30 2018-05-30
PCT/US2019/019065 WO2019165156A1 (en) 2018-02-23 2019-02-22 Cd83-binding chimeric antigen receptors

Publications (1)

Publication Number Publication Date
EA202092006A1 true EA202092006A1 (en) 2020-11-20

Family

ID=73649849

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092006A EA202092006A1 (en) 2018-05-30 2019-02-22 CD83-BINDING CHIMERIC ANTIGENIC RECEPTORS

Country Status (1)

Country Link
EA (1) EA202092006A1 (en)

Similar Documents

Publication Publication Date Title
PH12020500632A1 (en) Cd83-binding chimerix antigen receptors
MX2021005022A (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d).
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
MX2020010241A (en) Cellular immunotherapy compositions and uses thereof.
EA201992469A1 (en) ANTIGEN SPECIFIC IMMUNE EFFECTIVE CELLS
EA201790624A1 (en) AIMING OF CYTOTOXIC CELLS WITH CHEMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
MX2021009087A (en) Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1).
WO2017011804A8 (en) Engineered cells for adoptive cell therapy
WO2016011210A3 (en) Engineered cells for adoptive cell therapy
AR110676A1 (en) TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS
EA202092945A1 (en) DIFFERENT ANTIGEN BINDING DOMAINS, NEW PLATFORMS AND OTHER IMPROVEMENTS FOR CELL THERAPY
PH12020551671A1 (en) Chimeric receptors to dll3 and methods of use thereof
EA202091982A1 (en) Chimeric antigenic receptor to the receptor of IL-13 ALPHA 2 (IL13R2) for tumor-specific T-cell immunotherapy
MX2020010235A (en) Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof.
MX2017005344A (en) Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy.
MX2019014008A (en) Compositions and methods for immunotherapy.
JP2018524987A5 (en)
MX370173B (en) Cs1-specific chimeric antigen receptor engineered immune effector cells.
MX2022015062A (en) Novel constructs for chimeric antigen receptors.
MX2020007281A (en) Compositions and methods for targeting cd99-expressing cancers.
MX2020007338A (en) Compositions and methods for targeting clec12a-expressing cancers.
MX2019015484A (en) Chimeric antigen receptors with mutated cd28 costimulatory domains.
MX2020007357A (en) Pd1-specific chimeric antigen receptor as an immunotherapy.
CR20210091A (en) Chimeric receptors to steap1 and methods of use thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof